EXOSOME THERAPY - CELLTIX
|
STEM CELL THERAPY - CELLTIMAX
|
CelltiX is a type of extracellular vesicle from Umbilical Cord-Derived Mesenchymal Stem Cells (MSCs) manufactured in a cGMP-compliant facility. It is a novel form of a major paracrine factor released by MSCs into a culture medium, which plays an important role in a wide range of biological processes.
|
CelltiMax is a product derived from human umbilical cord-derived Mesenchymal Stem Cells (MSCs). The cells are cultured, then administered to the patient via intramuscular or intravenous injection.
The cells have low immunogenicity making them safe, well-tolerated and free of side effects. They have the ability to differentiate into specialized cells with specific functions for various parts of the body, and can reduce inflammation, repair, renew, regenerate, and replace damaged cells. |
CELLTINK
CelltiNK is a type of cytotoxic lymphocyte critical to the innate immune system. The role CelltiNK plays is analogous to that of cytotoxic T cells in the human adaptive immune response.
CelltiNK provides rapid responses to virus-infected cells, acting within days after being administered and responding to tumour formations. Typically, immune cells detect major histocompatibility complex (MHC) present on infected cell surfaces, triggering a cytokine release, and causing tumour lysis or apoptosis. CelltiNK can apply to replace the insufficient Natural Killer cells (NK cells) in cancer patient body Natural killer (NK) cells are effector lymphocytes of the innate immune system that control several types of tumors and microbial infections by limiting their spread and subsequent tissue damage. |
CELLTISS
CelltiSS is a conditioned media formulated for topical administration to wound areas; used to treat and manage wounds and major skin loss. CelltiSS consists of various types of bioactive factors secreted by fibroblasts. The conditioned media is obtained from a cell culture collected at 80-90% confluency of the culture, which is the confluency at which the cells are in a mitotic phase, and there is maximum production of bioactive factors.
|
CELL TISSUE TECHNOLOGY SDN BHD
Malaysia's FIRST Tissue Engineering Firm |
|